Anti-virals Flashcards
- State the stage in the viral life cycle affected by each drug.
Antiviral drugs are all virustatic, they are active only against replicating viruses and do not effect latent virus
- Explain how each drug selectively interferes with viral rather than cellular processes.
.
- Explain why acyclovir and ganciclovir differ in their effectiveness toward HSV and CMV.
Acyclovir and ganciclovir are phosphorylated by different proteins, encoded by different viral genes
What viruses does Acyclovir address, what is it used for and how is it selective.
viruses: HSV, VZV
selectivity: affinity for the enzyme thymidine kinase encoded by HSV and VZV
- Reduces duration and frequency of G-HSV outbreaks
- decreases lesions, duration of symptoms and viral shedding of varicella patients
- DOC with HSV encephalitis, neonatal
What is the MOA of acyclovir and what are concerns when using it as treatment.
requires 3 phosphorylation steps (first two by viral kinases), competes at viral DNA polymerase and results in chain termination
resistance is through alterations in TK or DNA polymerase
generally well tolerated and some renal or neurological toxicity, bioavailability is low
What viruses does Valacyclovir address, what is it used for and what are possible side effects
HSV, VZV, and HCMV
- 1st and recurrent genital herpes, herpes labialis and acute zoster
- topical penciclovir available for herpes libialis
Well tolerated, NV, rash; high doses cause confusion, hallucinations and seizures
What viruses does Famciclovir address, what is it used for and how is it selective?
HSV 1,2; VZV, EBV and HBV
- 1st and recurrent genital herpes, herpes labialis and acute zoster
- topical penciclovir available for herpes libialis
What is the MOA and mechanism of resistance. of Famciclovir?
Activation phosphor. Catalyzed by virus specific thymidine kinase; competitive inhibition of DNA polymerase (penciclovir does not cause chain termination)
Resistance: thymidine kinase-deficient
- Bioavailability of penciclovir from PO famciclovir is 70%
- generally well tolerated, ND, headache may occur
What is the MOA of Ganciclovir and what are methods of resistance?
required before inhibits DNA polymerase; competitively inhibits DNA polymerase and chain termination
Initial phosphorylation by protein kinase phophotranferase UL97, increases with duration of use or DNA polymerase (higher levels of resistance and potential cross-resist.)
What viruses does Ganciclovir address, what is it used for and what are possible side effects
HSV, VZV, EBV, HHV6,7 and HCMV
- ocular:dual therapy with Foscarnet
- CMV colitis, esophagitis, pneumonitis in ImmComp.
- prevention of end organ CMV in AIDS
- bioavailablity is low
- myelosuppression esp. after IV
- ND, fever, rash, headache, insomnia and peripheral neuropathy
- CNS toxicity rarely
- teratogenic and carcinogenic at high doses
What are the MOA, uses and side effects of Valgancivlovir.
L-valyl ester prodrug of ganciclovir
used in CMV retinitis in AIDS or prevention of CMV in high risk kidney and heart transplant
Initial phosphorylation by protein kinase phophotranferase UL97, increases with duration of use or DNA polymerase (higher levels of resistance and potential cross-resist.)
What viruses is Cidofovir used against?
HSV1,2; VZV, EBV, HHV 6, 8; HCMV
- also against adenovirus, poxvirus, polyomaviruses and human papilloma virus
- IV retinitis, given with probenecid, not directly injected
What are the method of action and resistance of Cidofovir? What are important concerns for adverse effects?
MOA: Potent inhibitor of and as an alternative substrate for viral DNA polymerase
agent is active independent of viral enzymes
-resistant strains retain susceptibility to foscarnet
- long half-life
- elimination by renal secretion
What viruses is Telbivudine used against and how is it used?
Hep B and C
tx of HBV by:
- suppress HBC DNA to undetectable levels
- seroconversion from neg to pos.
- reduction in elevated transaminase levels
What is the MOA of Telbivudine and what are concerns regarding adverse effects?
Activated by cellular kinases, competitively inhibits HBV DNA polymerase and chain termination (active independent of viral enzymes)
- wide tissue distribution, excretion is renal
- mild effects of fatigue, headache, abdominal pain, URI, increased creatine phosphokinase levels, NV
- lactic acidosis, severe hepatomegaly with steatosis